Immunovant, Inc., a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, announced that it will report initial IMVT-1402 Phase 1 results on Tuesday, September 26, 2023.
Immunovant, Inc., a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, announced that it will report initial IMVT-1402 Phase 1 results on Tuesday, September 26, 2023.